Immunovant Inc (IMVT) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Immunovant Inc stock $20.65, price $33.28, that is 38.0% below the price, quality 32 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
🚩Competitor data shifts landscape for lead candidate🚩Rivals like argenx could capture autoimmune market share🚩Regulatory delays could block IMVT-1402 approval
Watch Immunovant Inc for free: we tell you when fair value or trend changes.Watch for free
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases.
Show moreShow less
It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Stock analysis
Immunovant Inc (IMVT) currently trades at $33.28, while our estimate is $20.65, 38% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $15.49 (bear) to $25.81 (bull), the price of $33.28 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Immunovant Inc reported revenue of $0 in FY2026 versus $0 in FY2022. Reported net income was −$506M in FY2026.
Key figures
Market cap $6.6B Mid · EPS (TTM) $−2.56 · Return on equity −86.5% · Return on assets (EBIT) −46.8% (5-year average) · Free cash flow −$407M · Net cash $902M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 51% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −38%, IMVT screens richer than that median.
Fair Value
Bear$15.49Fair Value $20.65Bull$25.81
Price $33.28 · Downside -38.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Quality Score breakdown
Overall quality32/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability0
How much profit the company makes from its sales and capital
Quality Growth53
Are margins and returns getting better?
Cashflow20
Do the profits arrive as real cash?
Financial strength100
Debt, balance sheet and risk of trouble
Investment0
Does it invest with discipline instead of growing at any price?
Low Volatility39
How calm the share price moves, does not count
Price momentum48
Price momentum of the last 3 to 12 months, does not count
SaleAndrew J. FromkinDirector2× since Dec 1, 2025: 244,200 shares, avg. $32.58$8.0MMay 28, 2026
SaleRobert Graham SusmanDirector2,502 shares at $27.17$67,979May 1, 202610b5-1 plan
BuyRoivant Sciences Ltd.Director, 10% owner16,666,666 shares at $21.00$350.0MDec 12, 2025
SaleDouglas J. HughesDirector15,000 shares at $23.24$348,665Dec 1, 202510b5-1 plan
Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
News mood ⓘNews mood, the average tone of recent news (88 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: Immunovant holds a narrow moat in biotechnology but its main weakness is the pre-revenue stage with ongoing losses and a narrowing pipeline.
Main risk: Established competitors such as argenx with its approved Vyvgart could take customers in overlapping indications like myasthenia gravis or Graves’ disease and pressure prices or margins for IMVT-1402.
Bull case: Immunovant could leverage deeper IgG reductions and a convenient subcutaneous profile of IMVT-1402 to differentiate from rivals like argenx and secure regulatory approvals across multiple indications.
Bear case: If argenx and other FcRn rivals dominate key indications or regulatory setbacks halt IMVT-1402 development, the company might never generate product revenue and could face discontinuation of operations.
Immunovant deprioritized further development of its lead candidate beyond the ongoing Sjögren’s Phase 2 trial after competitor data shifted the landscape. The recent rheumatoid arthritis results met the primary endpoint yet left some secondary measures short of significance, with FDA talks still ahead. Our models view the stock as overvalued. Will focused execution on the remaining programs deliver more than the narrowing pipeline takes away?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Beats the industry median on 0/4 measures
Overall it trails its industry peers.
Valuation
Quality Score32 · Below median
Fair Value upside−38.0% · Below median
Profitability
Return on assets−52.8% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Immunovant Inc Fair Value". https://www.fairvalue-calculator.com/stock/IMVT
Frequently asked questions
Is Immunovant Inc (IMVT) overvalued or undervalued?
As of Nov 15, 2026, our estimate of fair value is $20.65 versus a price of $33.28, about 38% lower (overvalued).
What is the fair value of IMVT?
Our estimate for Immunovant Inc is $20.65 (as of Nov 15, 2026), built from audited fundamentals. The current price: $33.28.
What is the quality score of IMVT?
Immunovant Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Immunovant Inc (IMVT)?
Our calculated price target is the estimate of $20.65 (as of Nov 15, 2026). Cautious scenario $15.49, optimistic scenario $25.81. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Immunovant Inc stock forecast for 2026?
Our estimate puts fair value at $20.65, about 38% lower versus a price of $33.28 (overvalued). Cautious scenario $15.49, optimistic scenario $25.81. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Immunovant Inc (IMVT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Immunovant Inc it is $20.65 per share (as of Nov 15, 2026), against a price of $33.28.
Is Immunovant Inc stock overvalued or undervalued in 2026?
As of Nov 15, 2026, IMVT trades above its calculated fair value: price $33.28, fair value $20.65, a gap of about −38% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IMVT?
No. The price is what the market pays today ($33.28); the fair value is what the company's own numbers justify ($20.65). For Immunovant Inc the two are $12.63 per share apart. That gap is exactly why we show both numbers side by side.
How much is Immunovant Inc worth?
The market values Immunovant Inc at about $6.6B (market capitalisation, as of Nov 15, 2026). Per share that is $33.28; our models calculate a fair value of $20.65 per share.
What do the bullish and bearish scenarios say about IMVT?
Our models span a range for Immunovant Inc: cautious scenario $15.49, base $20.65, optimistic $25.81 per share (as of Nov 15, 2026, price $33.28). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Immunovant Inc (IMVT)?
Balance-sheet figures for Immunovant Inc (as of Nov 15, 2026): return on equity −86.5%. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is IMVT from its 52-week high?
Immunovant Inc trades at $33.28, about 26% below its 52-week high of $44.96 and 51% above the low of $22.02 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $20.65 is for.
Which stocks are comparable to Immunovant Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Immunovant Inc stock attractive at the current price?
The data as of Nov 15, 2026: price $33.28, calculated fair value $20.65 (−38%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Immunovant Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Immunovant Inc (IMVT)?
The closing price on Nov 16, 2026 was $33.28. Our estimate is $20.65, about 38% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Immunovant Inc right now?
The price sits above even our optimistic bull case ($25.81). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Immunovant Inc
How large is the market capitalisation of Immunovant Inc (IMVT)?
The market capitalisation of Immunovant Inc is $6.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Immunovant Inc (IMVT)?
Earnings per share at Immunovant Inc are $−2.56. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Immunovant Inc (IMVT)?
The return on equity (ROE) of Immunovant Inc is −86.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Immunovant Inc (IMVT)?
On an EBIT basis the return on assets of Immunovant Inc is −46.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Immunovant Inc (IMVT) generate?
The free cash flow of Immunovant Inc is −$407M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Immunovant Inc (IMVT) hold?
Immunovant Inc holds more cash than debt, $902M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Immunovant Inc in the live analysis
One click puts Immunovant Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.